Role of transglutaminase 2 in celiac disease pathogenesis

Seminars in Immunopathology

Volumn 34, Issue 4, 2012, Pages 513-522

  Klöck, Cornelius ^a   DiRaimondo, Thomas R ^b   Khosla, Chaitan ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b Stanford University   (United States)

Author keywords

Celiac disease . Transglutaminase . Gluten

Indexed keywords

ACRYLAMIDOARYLSULFONAMIDE; ACYLIDENE OXINDOLE; AMINOETHYL ARYLKETONE; CINNAMOYL KETONE; ENZYME INHIBITOR; GAMMA INTERFERON; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; THIENOPYRIMIDINONE HYDRAZIDE; THIOIMIDAZOLIUM DERIVATIVE; THIOREDOXIN 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; CATALYSIS; CELIAC DISEASE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CRYSTAL STRUCTURE; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTAKE; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW;

ANIMALS; CELIAC DISEASE; ENZYME ACTIVATION; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HUMANS; TRANSGLUTAMINASES;

EID: 84866121549     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-012-0305-0     Document Type: Review

References (110)

1. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: Nature's biological glues. Biochem J 368(Pt 2):377-396
2. Sollid LM (2002) Coeliac disease: Dissecting a complex inflammatory disorder. Nat Rev Immunol 2(9):647-655
3. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM (1994) Gh: A GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264 (5165):1593-1596
4. HasegawaG, SuwaM, IchikawaY, Ohtsuka T, Kumagai S,Kikuchi M, Sato Y, Saito Y (2003) A novel function of tissue-type transglutaminase: Protein disulphide isomerase. Biochem J 373(Pt 3):793-803
5. Mishra S, Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: Identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279(23):23863-23868
6. Fesus L, Piacentini M (2002) Transglutaminase 2: An enigmatic enzyme with diverse functions. Trends Biochem Sci 27(10):534-539
7. Park D, Choi SS, Ha K-S (2010) Transglutaminase 2: A multifunctional protein in multiple subcellular compartments. Amino Acids 39(3):619-631
8. Rodolfo C, Mormone E, Matarrese P, Ciccosanti F, Farrace MG, Garofano E, Piredda L, Fimia GM, Malorni W, Piacentini M (2004) Tissue transglutaminase is a multifunctional BH3-only protein. J Biol Chem 279(52):54783-54792
9. Malorni W, Farrace MG, Matarrese P et al (2009) The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: Implications for mitochondrial-dependent apoptosis. Cell Death Differ 16(11):1480-1492
10. Lesort M, Attanavanich K, Zhang J, Johnson GVW (1998) Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem 273(20):11991-11994
11. Peng X, Zhang Y, Zhang H, Graner S, Williams JF, Levitt ML, Lokshin A (1999) Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett 446 (1):35-39
12. Zemskov EA, Mikhailenko I, Hsia R-C, Zaritskaya L, Belkin AM (2011) Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes. PLoS One 6(4):e19414
13. Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li X, Griffin M (2012) Characterization of the heparin binding site of tissue transglutaminase: Its importance in the enzyme's cell surface targeting, matrix deposition and cell signalling. J Biol Chem. doi:10.1074/jbc.M111.294819
14. Singh US, Pan J (2005) Transglutaminase and cell-survival signaling. Prog Exp Tumor Res 38:75-88
15. Verderio EAM, Johnson TS, Griffin M (2005) Transglutaminases in wound healing and inflammation. Prog Exp Tumor Res 38:89-114
16. Lorand L, Graham RM (2003) Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nat Rev Mol Biol 4(2):140-156
17. Ientile R, Caccamo D, Griffin M (2007) Tissue transglutaminase and the stress response. Amino Acids 33(2):385-394
18. Collighan RJ, Griffin M (2009) Transglutaminase 2 cross-linking of matrix proteins: Biological significance and medical applications. Amino Acids 36(4):659-670
19. Belkin AM (2011) Extracellular TG2: Emerging functions and regulation. FEBS J 278(24):4704-4716
20. Fésüs L, Szondy Z (2005) Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 579(15):3297-3302
21. Gaudry CA, Verderio E, Aeschlimann D, Cox A, Smith C, Griffin M (1999) Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal betasandwich domain. J Biol Chem 274(43):30707-30714
22. Gaudry CA,Verderio E, Jones RA, Smith C, GriffinM(1999) Tissue transglutaminase is an important player at the surface of human endothelial cells: Evidence for its externalization and its colocalization with the beta(1) integrin. Exp Cell Res 252(1):104-113
23. Zemskov E, Janiak A, Hang J, Waghray A (2006) The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 1:1057-1076
24. Telci D, Griffin M (2006) Tissue transglutaminase (TG2)-a wound response enzyme. Front Biosci 11(4):867-882
25. Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS (1999) Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 13(13):1787-1795
26. Nunes I, Gleizes PE, Metz CN, Rifkin DB (1997) Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136(5):1151-1163
27. Mehta K, Fok JY, Mangala LS (2006) Tissue transglutaminase: From biological glue to cell survival cues. Front Biosci 11(3):173-185
28. Gundemir S, Colak G, Tucholski J, Johnson GVW (2011) Transglutaminase 2: A molecular Swiss army knife. Biochim Biophys Acta 1823(2):406-419
29. De Laurenzi V, Melino G (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21(1):148
30. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM (2001) Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276(23):20673-20678
31. Sarang Z, Tóth B, Balajthy Z, Köröskényi K, Garabuczi E, Fésüs L, Szondy Z (2009) Some lessons from the tissue transglutaminase knockout mouse. Amino Acids 36(4):625-631
32. Siegel M, Strnad P,Watts RE, Choi K, Jabri B, OmaryMB, Khosla C (2008) Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 3(3):e1861
33. Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C, Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285(33):25402-25409
34. Jin X, Stamnaes J, Kloeck C, Diraimondo TR, Sollid LM, Khosla C (2011) Activation of extracellular transglutaminase 2 by thioredoxin. J Biol Chem 286(43):37866-37873
35. DiRaimondo TR, Klöck C, Khosla C (2012) Interferon-γ Activates transglutaminase 2 via a phosphatidylinositol-3-kinase dependent pathway: Implications for celiac sprue therapy. J Pharmacol Exp Ther 341(1):104-114
36. Bergamini CM (1988) GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase. FEBS Lett 239(2):255-258
37. Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM, Iismaa SE (2006) Mutation of a critical arginine in the GTPbinding site of transglutaminase 2 disinhibits intracellular crosslinking activity. J Biol Chem 281(18):12603-12609
38. Bergamini CM, Signorini M, Poltronieri L (1987) Inhibition of erythrocyte transglutaminase by GTP. Biochim Biophys Acta 916 (1):149-151
39. Bergamini CM, Dondi A, Lanzara Vet al (2010) Thermodynamics of binding of regulatory ligands to tissue transglutaminase. Amino acids 39(1):297-304
40. Pinkas DM, Strop P, Brunger AT, Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5(12):2788-2796
41. Liu S, Cerione RA, Clardy J (2002) Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci USA 99(5):2743-2747
42. Antonyak MA, Jansen JM, Miller AM, Ly TK, Endo M, Cerione RA (2006) Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA 103 (49):18609-18614
43. Lai T-S, Liu Y, Li W, Greenberg CS (2007) Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells. FASEB J 21(14):4131-4143
44. Citron BA, Suo Z, SantaCruz K, Davies PJA, Qin F, Festoff BW (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40(1):69-78
45. Kojima S, Kuo T-F, Tatsukawa H (2012) Regulation of transglutaminase- mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 27(Suppl 2):52-57
46. Monsonego A, Friedmann I, Shani Y, Eisenstein M, Schwartz M (1998) GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase. J Mol Biol 282(4):713-720
47. Monsonego A, Shani Y, Friedmann I, Paas Y, Eizenberg O, Schwartz M (1997) Expression of GTP-dependent and GTPindependent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem 272(6):3724-3732
48. Sjöström H, Lundin KE, Molberg O et al (1998) Identification of a gliadin T-cell epitope in coeliac disease: General importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 48(2):111-115
49. Fleckenstein B,Molberg Ø, Qiao S-W, Schmid DG, von derMülbe F, Elgstøen K, Jung G, Sollid LM (2002) Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 277(37):34109-34116
50. Vader LW, de Ru A, van der Wal Y, Kooy YMC, Benckhuijsen W, Mearin ML, Drijfhout JW, van Veelen P, Koning F (2002) Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 195(5):643-649
51. Piper JL, Gray GM, Khosla C (2002) High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: Implications for celiac sprue. Biochemistry 41(1):386-393
52. Molberg O, Mcadam SN, Körner R et al (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4(6):713-717
53. van deWalY, KooyY, vanVeelen P, Peña S, Mearin L, Papadopoulos G, Koning F (1998) Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 161(4):1585-1588
54. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS (2000) In vivo antigen challenge in celiac disease identifies a single transglutaminase- modified peptide as the dominant A-gliadin Tcell epitope. Nat Med 6(3):337-342
55. Arentz-Hansen H, Körner R, Molberg O et al (2000) The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 191(4):603-612
56. Kim C-Y, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101(12):4175-4179
57. Henderson KN, Tye-Din JA, Reid HH et al (2007) A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 27(1):23-34
58. DieterichW, Laag E, Schöpper H, Volta U, Ferguson A, Gillett H, Riecken EO, Schuppan D (1998) Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterol 115 (6):1317-1321
59. Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabó IR, Sarnesto A, Savilahti E, Collin P, Mäki M (1998) Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterol 115(6):1322-1328
60. Caja S, Mäki M, Kaukinen K, Lindfors K (2011) Antibodies in celiac disease: Implications beyond diagnostics. Cell Mol Immunol 8(2):103-109
61. Mäki M (1995) The humoral immune system in coeliac disease. Baillieres Clin Gastroenterol 9(2):231-249
62. Rantala I, Mäki M, Laasonen A, Visakorpi JK (1985) Periodate-lysine-paraformaldehyde as fixative for the study of duodenal mucosa. Morphologic and immunohistochemical results at light and electron microscopic levels. Acta Pathol Microbiol Immunol Scand A 93(4):165-173
63. Korponay-Szabó IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs L, Mäki M (2004) In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 53(5):641-648
64. Halttunen T, Mäki M (1999) Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterol 116(3):566-572
65. BaroneMV, Caputo I, RibeccoMT,MaglioM,Marzari R, Sblattero D, Troncone R, Auricchio S, Esposito C (2007) Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterol 132(4):1245-1253
66. Zanoni G, Navone R, Lunardi C et al (2006) In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 3(9): E358
67. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M et al (2008) Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J ExpMed 205(1):143-154
68. Simon-Vecsei Z, Király R, Bagossi P et al (2012) A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc Natl Acad Sci USA 109(2):431-436
69. De Re V, Simula MP, Notarpietro A, Canzonieri V, Cannizzaro R, Toffoli G (2010) Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease? Gut 59(12):1730-1731
70. Luciani A, Villella VR, Vasaturo A et al (2010) Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase- mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 59(3):311-319
71. Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2(10):748-759
72. Rizzo G, Fiorucci S (2006) PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 6(4):421-427
73. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530(1-2):70-80
74. Bethune MT, Siegel M, Howles-Banerji S, Khosla C (2009) Interferon-gamma released by gluten-stimulated celiac diseasespecific intestinal T cells enhances the transepithelial flux of gluten peptides. J Pharmacol Exp Ther 329(2):657-668
75. Ootani A, Li X, Sangiorgi E et al (2009) Sustained in vitro intestinal epithelial culture within aWnt-dependent stem cell niche. Nat Med 15(6):701-706
76. Snippert HJ, van der Flier LG, Sato T et al (2010) Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143(1):134-144
77. Black KE, Murray JA, David CS (2002) HLA-DQ determines the response to exogenous wheat proteins: A model of gluten sensitivity in transgenic knockout mice. J Immunol 169(10):5595-5600
78. Chen Z, Dudek N, Wijburg O, Strugnell R, Brown L, Deliyannis G, Jackson D, Koentgen F, Gordon T, McCluskey J (2002) A 320-kilobase artificial chromosome encoding the human HLA DR3-DQ2 MHC haplotype confers HLA restriction in transgenic mice. J Immunol 168(6):3050-3056
79. Hovhannisyan Z, Weiss A, Martin A et al (2008) The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 456(7221):534-538
80. de Kauwe AL, Chen Z, Anderson RP, Keech CL, Price JD, Wijburg O, Jackson DC, Ladhams J, Allison J, McCluskey J (2009) Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J Immunol 182(12):7440-7450
81. Ohta N, Hiroi T, Kweon M-N, Kinoshita N, Jang MH, Mashimo T, Miyazaki J-I, Kiyono H (2002) IL-15-dependent activationinduced cell death-resistant Th1 type CD8 alpha beta + NK1.1+ T cells for the development of small intestinal inflammation. J Immunol 169(1):460-468
82. DePaolo RW, Abadie V, Tang F et al (2011) Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471(7337):220-224
83. Yokoyama S, Watanabe N, Sato N, Perera P-Y, Filkoski L, Tanaka T, Miyasaka M, Waldmann TA, Hiroi T, Perera LP (2009) Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci USA 106(37):15849-15854
84. Sollid LM, Khosla C (2005) Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2(3):140-147
85. Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115(2):232-245
86. Marrano C, de Macédo P, Keillor JW (2001) Evaluation of novel dipeptide-bound alpha, beta-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg Med Chem 9(7):1923-1928
87. Wodzinska JM (2005) Transglutaminases as targets for pharmacological inhibition. Mini Rev Med Chem 5(3):279-292
88. Hausch F, Halttunen T,MäkiM,Khosla C (2003) Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol 10(3):225-231
89. Chittur SV, Klem TJ, Shafer CM, Davisson VJ (2001) Mechanism for acivicin inactivation of triad glutamine amidotransferases. Biochemistry 40(4):876-887
90. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C (2005) Chemistry and biology of dihydroisoxazole derivatives: Selective inhibitors of human transglutaminase 2. Chem Biol 12(4):469-475
91. Watts RE, Siegel M, Khosla C (2006) Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 49(25):7493-7501
92. Pardin C, Pelletier JN, Lubell WD, Keillor JW (2008) Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 73(15):5766-5775
93. Pardin C, Roy I, Chica RA, Bonneil E, Thibault P, Lubell WD, Pelletier JN, Keillor JW (2009) Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors. Biochemistry 48(15):3346-3353
94. PrimeME, Andersen OA, Barker J et al (2012) Discovery and SAR of potent and selective covalent inhibitors of transglutaminase 2 for huntington's disease. J Med Chem. doi:10.1021/jm201310y
95. Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM (1994) Transglutaminase inhibition by 2-[(2-oxopropyl) thio] imidazolium derivatives: Mechanism of factor XIIIa inactivation. Biochemistry 33(33):10109-10119
96. Ozaki S, Ebisui E, Hamada K, Goto J-I, Suzuki AZ, Terauchi A, Mikoshiba K (2010) Potent transglutaminase inhibitors, aryl betaaminoethyl ketones. Bioorg Med Chem Lett 20(3):1141-1144
97. Lai T-S, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, StrittmatterWJ,Greenberg CS (2008) Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol 15(9):969-978
98. Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE, Courtney S, Scheel A, Macdonald D (2010) A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen 15(5):478-487
99. Duval E, Case A, Stein RL, Cuny GD (2005) Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett 15(7):1885-1889
100. Klöck C, Jin X, Choi K, Khosla C, Madrid PB, Spencer A, Raimundo BC, Boardman P, Lanza G, Griffin JH (2011) Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett 21(9):2692-2696
101. Case A, Stein RL (2007) Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry 46(4):1106-1115
102. Dafik L, Albertelli M, Stamnaes J, Sollid LM, Khosla C (2012) Activation and inhibition of transglutaminase 2 in mice. PLoS One 7(2):e30642
103. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Rispo A, Griffin M, Issekutz T, Quaratino S, Londei M (2005) Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterol 129(5):1400-1413
104. Shan L, Molberg Ø, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C (2002) Structural basis for gluten intolerance in celiac sprue. Science 297(5590):2275-2279
105. VaderW, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, Spaenij L, Koning F (2003) The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 100 (21):12390-12395
106. Kooy-Winkelaar Y, van Lummel M, Moustakas AK et al (2011) Gluten-specific T cells cross-react between HLA-DQ8 and the HLA-DQ2α/DQ8β transdimer. J Immunol 187(10):5123-5129
107. Nemes Z, Petrovski G, Csosz E, Fésüs L (2005) Structurefunction relationships of transglutaminases-a contemporary view. Prog Exp Tumor Res 38:19-36
108. Lorand L, Conrad SM (1984) Transglutaminases. Mol Cell Biochem 58(1-2):9-35
109. Facchiano A, Facchiano F (2005) Transglutaminases and their substrates. Prog Exp Tumor Res 38:37-57
110. Schrode J, Folk JE (1978) Transglutaminase-catalyzed crosslinking through diamines and polyamines. J Biol Chem 253 (14):4837-4840